vs

Side-by-side financial comparison of EASTERN CO (EML) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

EASTERN CO is the larger business by last-quarter revenue ($55.3M vs $37.2M, roughly 1.5× Organogenesis Holdings Inc.). On growth, EASTERN CO posted the faster year-over-year revenue change (-22.4% vs -57.1%). Over the past eight quarters, EASTERN CO's revenue compounded faster (-0.6% CAGR vs -46.5%).

China Eastern Airlines is a major airline in China, headquartered in Changning, Shanghai. It is one of the three major airlines in the country, along with Air China and China Southern Airlines.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

EML vs ORGO — Head-to-Head

Bigger by revenue
EML
EML
1.5× larger
EML
$55.3M
$37.2M
ORGO
Growing faster (revenue YoY)
EML
EML
+34.7% gap
EML
-22.4%
-57.1%
ORGO
Faster 2-yr revenue CAGR
EML
EML
Annualised
EML
-0.6%
-46.5%
ORGO

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
EML
EML
ORGO
ORGO
Revenue
$55.3M
$37.2M
Net Profit
$578.9K
Gross Margin
22.3%
30.8%
Operating Margin
3.1%
-185.1%
Net Margin
1.0%
Revenue YoY
-22.4%
-57.1%
Net Profit YoY
103.8%
EPS (diluted)
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EML
EML
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$225.6M
Q3 25
$55.3M
$150.9M
Q2 25
$70.2M
$101.0M
Q1 25
$63.3M
$86.7M
Q4 24
$64.3M
$126.7M
Q3 24
$71.3M
$115.2M
Q2 24
$72.6M
$130.2M
Net Profit
EML
EML
ORGO
ORGO
Q1 26
Q4 25
$43.7M
Q3 25
$578.9K
$21.6M
Q2 25
$3.4M
$-9.4M
Q1 25
$1.9M
$-18.8M
Q4 24
$1.3M
$7.7M
Q3 24
$-15.3M
$12.3M
Q2 24
$3.5M
$-17.0M
Gross Margin
EML
EML
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
22.3%
Q2 25
23.3%
Q1 25
22.4%
72.6%
Q4 24
23.6%
75.5%
Q3 24
25.5%
76.7%
Q2 24
25.4%
77.6%
Operating Margin
EML
EML
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.1%
Q3 25
3.1%
13.7%
Q2 25
4.5%
-12.5%
Q1 25
5.1%
-30.9%
Q4 24
6.1%
8.1%
Q3 24
9.5%
5.4%
Q2 24
8.3%
-10.7%
Net Margin
EML
EML
ORGO
ORGO
Q1 26
Q4 25
19.4%
Q3 25
1.0%
14.3%
Q2 25
4.9%
-9.3%
Q1 25
3.1%
-21.7%
Q4 24
2.0%
6.1%
Q3 24
-21.5%
10.7%
Q2 24
4.8%
-13.1%
EPS (diluted)
EML
EML
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$0.10
$0.11
Q2 25
$0.56
$-0.10
Q1 25
$0.32
$-0.17
Q4 24
$0.22
$0.05
Q3 24
$-2.46
$0.09
Q2 24
$0.56
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EML
EML
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$9.2M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$124.3M
Total Assets
$220.0M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EML
EML
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$9.2M
$63.7M
Q2 25
$9.1M
$73.1M
Q1 25
$10.2M
$110.0M
Q4 24
$16.1M
$135.6M
Q3 24
$9.7M
$94.3M
Q2 24
$2.0M
$89.9M
Total Debt
EML
EML
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$42.2M
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
EML
EML
ORGO
ORGO
Q1 26
Q4 25
$300.1M
Q3 25
$124.3M
$255.1M
Q2 25
$124.4M
$233.2M
Q1 25
$121.0M
$242.9M
Q4 24
$120.7M
$262.9M
Q3 24
$119.2M
$278.5M
Q2 24
$136.5M
$263.5M
Total Assets
EML
EML
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$598.7M
Q3 25
$220.0M
$509.8M
Q2 25
$229.4M
$461.1M
Q1 25
$232.3M
$467.4M
Q4 24
$235.3M
$497.9M
Q3 24
$244.2M
$446.3M
Q2 24
$255.9M
$443.2M
Debt / Equity
EML
EML
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.35×
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EML
EML
ORGO
ORGO
Operating Cash FlowLast quarter
$3.1M
Free Cash FlowOCF − Capex
$3.1M
FCF MarginFCF / Revenue
5.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
5.38×
TTM Free Cash FlowTrailing 4 quarters
$12.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EML
EML
ORGO
ORGO
Q1 26
Q4 25
$39.4M
Q3 25
$3.1M
$3.1M
Q2 25
$3.8M
$-32.9M
Q1 25
$-1.8M
$-19.9M
Q4 24
$11.0M
$10.9M
Q3 24
$-2.9M
$8.7M
Q2 24
$8.4M
$4.7M
Free Cash Flow
EML
EML
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$3.1M
$844.0K
Q2 25
$3.0M
$-36.5M
Q1 25
$-2.7M
$-23.6M
Q4 24
$9.0M
$7.6M
Q3 24
$-7.7M
$6.1M
Q2 24
$7.3M
$2.9M
FCF Margin
EML
EML
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
5.5%
0.6%
Q2 25
4.3%
-36.1%
Q1 25
-4.3%
-27.2%
Q4 24
13.9%
6.0%
Q3 24
-10.8%
5.3%
Q2 24
10.1%
2.2%
Capex Intensity
EML
EML
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
0.1%
1.5%
Q2 25
1.1%
3.6%
Q1 25
1.3%
4.2%
Q4 24
3.2%
2.7%
Q3 24
6.7%
2.2%
Q2 24
1.5%
1.4%
Cash Conversion
EML
EML
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
5.38×
0.14×
Q2 25
1.09×
Q1 25
-0.95×
Q4 24
8.41×
1.43×
Q3 24
0.71×
Q2 24
2.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons